Hormonal treatments of acne;Les traitements hormonaux

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 1 II, 2003, Pages 142-147

  Faure, M ^a   Drapier Faure, E ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANTIANDROGEN; CYPROTERONE ACETATE; DIANE; DROSPIRENONE; ETHINYLESTRADIOL; GLUCOCORTICOID; ISOTRETINOIN; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE;

ACNE; ARTICLE; DRUG CHOICE; DRUG EFFICACY; HORMONAL THERAPY; HUMAN; JASMINE;

ACNE VULGARIS; ALDOSTERONE ANTAGONISTS; ANDROGEN ANTAGONISTS; CYPROTERONE ACETATE; ESTROGENS; GLUCOCORTICOIDS; HUMANS; PATIENT CARE PLANNING; PROGESTINS; SPIRONOLACTONE;

EID: 0037219616     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med 1995;98:S1A-89-94.
2. Drapier-Faure E, Faure M. Quelle est la place des traitements hormonaux dans l'acné? Ann Dermatol Venereol 2001;128:2S19-24.
3. Gianotti B, Carli P. Hormonal contraception and the skin. Eur J Contr Reprod Health Care 1998;3:17-9.
4. Redmond GP. Effectiveness of oral contraceptive in the treatment of acne. Contraception 1998;58:29S-33S.
5. Shaw JC. Antiandrogen and hormonal treatment of acne. Dermatol Clin 1996;14:803-11.
6. Thiboutot DM, Lookingbill DP. Hormonal therapy of acne. Dermatologic Therapy 1998;6:39-43.
7. Drapier-Faure E. Hyperandrogénies: traitement et contraception. Reprod Hum et Horm 1995;8:15-9.
8. Hammerstein J, Meckies J, Leo-Rossberg I, Moltz L. Use of cyproterone acetate in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975;6:827-36.
9. van Wayjen RG, van den Ende A. Experience in the long term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes 1995;103:241-51.
10. Vexiau P, Boudou P, Fiet J, Hardy N, Conard J, Consoli S, et al. 17 beta estradiol: oral or parenteral administration in hyperandrogenic women? metabolic tolerance in association with cyproterone acetate. Fertil Steril 1995;65:508-15.
11. Consoli SM, Vexiau P, Consoli SG, Abramovici Y. Acceptabilité, tolérance et impact sur la qualité de vie du traitement de la femme hirsute par l'acétate de cyprotérone. Comparaison de 2 schémas l'associant soit à l'estradiol per os, soit par voie transdermique. Contraception Fertilité Sexualité 1994;12:783-7.
12. Lubbos HG, Hasinski S, Rose LI, Pollock J. Adverse effects of spironolactone therapy in women with acne. Arch Dermatol 1998;134:1162-3.
13. Goodfellow A, Alaghband-Zadeh J, Carter G, Cream JJ, Holland S, Scully J, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984;111:209-14.
14. Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol 1986;115:227-32.
15. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985;112:124-5.
16. Hatwal A, Bhatt RP, Agrawal JK, Singh G, Bajpai HS. Spironolactone and cimetidine in treatment of acne. Acta Derm Venereol 1988;68:84-7.
17. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000;43:492-502.
18. Darney PD. The androgenicity of progestins. Am J Med 1995;98:104S-110S.
19. Mall-Haefeli M, Werner-Zodrow I, Huber PR, Darragh A, Lambe R. Effects of various combined oral contraceptives on sex steroids, gonadotrophins and SHBG. Irish Med J 1983;76:266-72.
20. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JHH. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990;41:345-52.
21. Coenen CMH, Thomas CMG, Borm GF, Hollanders JMG, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996;53:171-6.
22. Kuhnz W, Baumann A, Staks T, Dibbelt L, Knuppen R, Jütting G. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of the treatment on free and total testosterone levels in the serum. Contraception 1993;48:303-22.
23. Liukko P, Erkkola R, Bergink EW. Progestin-dependent effect on androgen levels during oral contraception. Int J Feto-Maternal Med 1988;1:15-20.
24. Murphy AA, Burkman RT, Cropp CS, Zacur HA, Smith BS. Effect of low dose oral contraceptive on gonadotrophins, androgens, and sex hormone binding globullin in non hirsute women. Fertil Steril 1990;53:35-9.
25. Hammond GL, Langley MS, Tech B, Robinson PA, Nummi S, Lund L. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertil Steril 1984;42:44-51.
26. Palatsi R, Hirvensalo E, Liukko P. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol 1984;64:517-23.
27. Thiboutot D, Gilliland K, Light J, Lookingbill D. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 1999;135:1041-5.
28. Vershoore M. Aspects hormonaux de l'acné. Ann Dermatol Venereol 1987;114:439-54.
29. Cibula D, Hill M, Vohradikova O, Kuzel D, Fanta M, Zivny J. The role of androgens in determining acne severity in adult women. Br Dermatol 2000;143:399-404.
30. Lemay A, Dodin Dewailly S, Grenier R, Huard J. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrin Metabolism 1990;71:8-14.
31. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception 1999;60:255-62.
32. Venturoli S, Porcu E, Gammi L. The effects of desogestrel and ethinylestradiol combination in normal and hyperandrogenic young girls: speculations on contraception in adolescence. Acta Europaea Fertilitatis 1988;19:129-34.
33. Nappi C, Farace MJ, Leone F, Minutolo M, Tommaselli AP, Montemagno U. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism. Eur J Obstet Gynecol Reprod Biol 1987;25:209-19.
34. Comparato MR, Yabur JA, Bajares M. Contraceptive efficacy and acceptabililty of a monophasic oral contraceptive containing 30 microg ethinylestradiol and 150 microg desogestrel in Latin American women. Adv Contracept 1998;14:15-26.
35. Mango D, Ricci S, Manna P, Miggiano GAD, Serra G. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 1996;53:163-70.
36. Halbe HW, deMelo NR, Bahamondes L, Petracco A, Lemgruber M, de Andrade RP, et al. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care 1998;3:113-20.
37. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinylestradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-22.
38. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinylestradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-54.
39. Olson WH, Lippman JS, Robisch DM. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Int J Fertil Womens Med 1998;43:286-90.
40. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized controlled trial of a low dose contraceptive containing 20 my of ethinylestradiol and 100 my of levonorgestrel for acne treatment. Fertil Steril 2001;76:461-8.
41. Leyden J, Shalita A, Hordinsky, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a low-dose oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial. J Am Acad Dermatol 2002;47:399-409.
42. Ekoe JM, Burckhardt P, Ruedi B. Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica 1980;160:398-404.
43. Levrier M, Degrelle H, Bestaux Y, Bourry-Moreno M, Brun JP, Sailly F. Efficacité sur l'acné des contraceptifs hormonaux. A propos d'une étude comparative Varnoline versus Diane® chez 69 femmes acnéiques. Rev Fr Gynecol Obstet 1988;83:7-9.
44. Spona J, Huber J, Schmidt JB. Ovulation inhibitory effect of SH B 209 AE (Diane 35®), a new antiandrogen-estrogen combination. In: Schindler AE. Antiandrogen-estrogen therapy for signs of androgenization. Berlin-New York: Walter de Gruyter 1987. New developments in biosciences 3, P51-8.
45. Higgins HP, Davies TG, Hutchinson PE. A study to investigate the mantenance of ovulation inhibition when patients switch over from Diane to Diane 35®, in: Schindler AE: Antiandrogen-estrogen therapy for signs of hyperandrogenization. Berlin-New York: Walter de Gruyter 1987. New developments in biosciences 3, P59-68.
46. Fugère P, Percival-Smith RKL, Lussier-Cacar S, Davignon J, Farquhar D. Cyproterone-acetate/ethinylestradiol in the treatment of acne. A comparative dose-response study of the estrogen component. Contraception 1990;42:225-34.
47. Aydinlik S, Kaufmanr J, Lachnit-Fixson U, Lehnert J. Long-term therapy of signs of androgenisation with a low-dosed antiandrogen-cestrogen combination. Clin Trials J 1990;27:392-402.
48. Audebert A, Emperair JC, Gauthier A, Hallonet P, Hedon B, Lopes P, Quereux C, et al. Etude clinique multicentrique d'une association de 35 microg d'éthinylestradiol et de 2 mg d'acétate de cyprotérone. Rev Fr Gynecol Obstet 1991;86:1-3.
49. Kaiser E. Klinische Erfahrungen mit Diane 35®, dem zur Zeitniedrigst dosierten antiandrogen wirkenden hormonalen Ovulationshemmer, bei leichten bis mittelstarken Androgenisierungserscheinungen der Frau. Geburtsh. u. Frauenheikl 1986;46:738-42.
50. Török L, Gimes R, Aydinilik S. Rezidivhaufigkeit von Akne und Seborrhoe nach der Behandlung mit einem antiandrogenhaltigen Kombinationspräparat. Dt Derm 1990;38:166-72.
51. Falsetti L, Ramazzotto F, Rosina B. Efficacy of combined ethinylestradiol and cyproterone acetate in acne and hirsutism in women with polycystic ovary syndrome. J Obstet Gynaecol 1997;17:565-8.
52. Gollnick H, Albring M, Brill K. The efficacy of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. J Derm Treatment 1998;9:71-9.
53. Gollnick H, Albring M, Brill K. Efficacité de l'acétate de cyprotérone oral associé à l'éthinylestradiol dans le traitement de l'acné tardive de type facial. Ann Endocrinol 1999;60:157-66.
54. Carlborg L. Comparaison de l'acétate de cyprotérone et du lévonorgestrel associé à l'éthinylestradiol dans le traitement de l'acné. Résultats d'une étude multicentrique. Contraception-fertilité-sexualité 1987;15:S1-4.
55. Erkkola R, Hirvonen E, Luikku J, Lumme R, Männiklö H, Aydinlik S. Les inhibiteurs de l'ovulation contenant de l'acétate de cyprotérone ou du désogestrel dans les traitements des troubles androgéniques. Acta Obstet Gynecol Scand 1990;69:61-5.
56. Dieben TO, Vromans L, Theeuwes A, Bennink HL. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane 35® in women with acne Contraception 1994;50:373-82.
57. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster A, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone actetate. Int J Fertil Menopausal Stud 1996;41:423-9.
58. Moore C, Luderschmidt C, Moltz L, Oettel M, Klinger G, Schreiber G. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®. Drugs of Today 1999;35:S69-78.
59. Zimmermann T, Wisser KH, Dietrich H. Effects of the dienogestcontaining oral contraceptive Valette® on skin and hair. Results of a postmarketing surveillance study. Drugs of Today 1999;35:S97-104.
60. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000;5:S25-33.
61. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:S4:2-15.
62. Rittmaster RS, Givner ML. Effect of daily and alternate day low dose prednisone on serum cortisol and adrenal androgens in hirsute women. J Clin Endocrinol Metab 1988;67:400-3.
63. Spritzer P, Billaud L, Thalabard JC. Cyproterone acetate versus hydrocortisone treatment of late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1990;70:642-5.
64. Chaspoux C, Lehucher-Ceyrac D, Morel P, Lefrancq H, Boudou P, Fiet J, et al. Acné de l'homme résistant à l'isotrétinoïne et responsabilité des androgénes: 9 cas, implications thérapeutiques. Ann Dermatol Venereol 1999;126:17-9.
65. Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol 1999;141:307-9.
66. Chivot M. Poussées inflammatoires et aggravations d'acné sous isotrétinoïne orale. Ann Dermatol Venereol 2001;128:224-8.